Related Experiment Video

Updated: May 29, 2026

Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes
12:12

Methods to Assess Beta Cell Death Mediated by Cytotoxic T Lymphocytes

Published on: June 16, 2011

Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy?

Daniel H van Raalte1, Michaela Diamant

  • 1Diabetes Centre, Department of Internal Medicine, VU University Medical Centre, Amsterdam, The Netherlands. d.vanraalte@vumc.nl

Diabetes Research and Clinical Practice
|August 26, 2011
PubMed

Insights

Type 2 diabetes involves beta-cell failure due to insulin resistance. Novel therapies like thiazolidinediones and incretin-based drugs may preserve beta-cell function by reducing glucolipotoxicity.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) is characterized by beta-cell dysfunction and insulin resistance.
  • Progressive decline in beta-cell function is a hallmark of T2DM, irrespective of treatment.
  • Glucolipotoxicity, driven by elevated glucose and fatty acids, accelerates beta-cell failure through ER stress, oxidative stress, and inflammation.

Purpose of the Study:

  • To review the impact of current and novel therapies on beta-cell function in T2DM.
  • To explore the mechanisms by which glucolipotoxicity affects beta-cell decline.
  • To evaluate the potential of thiazolidinediones (TZDs) and incretin-based therapies in preserving beta-cell function.

Main Methods:

  • Literature review of studies on T2DM pathophysiology and treatment.
  • Analysis of mechanisms underlying glucolipotoxicity (ER stress, oxidative stress, mitochondrial dysfunction, inflammation).
  • Examination of evidence for TZD and incretin-based therapies' effects on beta-cell function and mass.

Main Results:

  • Standard treatments like metformin and sulfonylureas offer temporary glycemic control but do not halt beta-cell decline.
  • Thiazolidinediones (TZDs) and incretin-based therapies show potential in preserving beta-cell function and mass.
  • These novel therapies may exert protective effects by mitigating glucolipotoxicity within beta cells.

Conclusions:

  • Glucolipotoxicity is a key driver of progressive beta-cell failure in T2DM.
  • TZDs and incretin-based therapies represent promising strategies for preserving beta-cell function.
  • Long-term clinical studies are needed to confirm the durability of these effects.

More Related Videos

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

A Model of Chronic Nutrient Infusion in the Rat08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

Related Concept Videos

Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...